Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 22 Dec 23 EFFECT Notice of effectiveness
- 20 Dec 23 POS AM Prospectus update (post-effective amendment)
- 12 May 22 424B5 Prospectus supplement for primary offering
- 28 Oct 21 424B5 Prospectus supplement for primary offering
- 27 Oct 21 424B5 Prospectus supplement for primary offering
- 20 Jul 21 424B5 Prospectus supplement for primary offering
- 20 Jul 21 FWP Free writing prospectus
- 19 Jul 21 FWP Free writing prospectus
- 19 Jul 21 424B5 Prospectus supplement for primary offering
- 18 Mar 21 EFFECT Notice of effectiveness
- 17 Mar 21 424B5 Prospectus supplement for primary offering
-
9 Mar 21 S-3 Shelf registration
FRTX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-3) and related Prospectus of Brickell Biotech, Inc. for the registration of up to $150,000,000 of its common stock, preferred stock, debt securities, stock purchase contracts, warrants, rights and units, and to the incorporation by reference therein of our report dated March 9, 2021, with respect to the consolidated financial statements of Brickell Biotech, Inc., included in Brickell Biotech Inc.’s Annual Report (Form 10-K) for the year ended December 31, 2020, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP |
Denver, Colorado
March 9, 2021